Media coverage about Novocure (NASDAQ:NVCR) has trended somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Novocure earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 44.9357836916583 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern’s scoring:
- Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control (finance.yahoo.com)
- Novocure Ltd (NVCR) Expected to Post Quarterly Sales of $66.17 Million (americanbankingnews.com)
- This brain cancer drug stock has been on a tear (finance.yahoo.com)
- -$0.14 EPS Expected for Novocure Ltd (NVCR) This Quarter (americanbankingnews.com)
NVCR has been the subject of a number of research reports. BidaskClub upgraded shares of Novocure from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 12th. Mizuho reiterated a “buy” rating and issued a $32.00 price objective on shares of Novocure in a research note on Wednesday, June 13th. Evercore ISI initiated coverage on shares of Novocure in a research note on Monday, July 16th. They issued an “outperform” rating and a $46.00 price objective for the company. Deutsche Bank cut shares of Novocure from a “buy” rating to a “hold” rating in a research note on Wednesday, July 25th. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Novocure from $30.00 to $44.00 and gave the stock an “overweight” rating in a research note on Friday, July 27th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $34.67.
Shares of Novocure stock opened at $43.10 on Thursday. Novocure has a twelve month low of $16.10 and a twelve month high of $45.45. The company has a quick ratio of 5.97, a current ratio of 6.41 and a debt-to-equity ratio of 1.33. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of -61.57 and a beta of 3.33.
Novocure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, July 26th. The medical equipment provider reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Novocure had a negative return on equity of 52.34% and a negative net margin of 26.99%. The business had revenue of $61.50 million during the quarter, compared to analyst estimates of $59.53 million. The company’s revenue for the quarter was up 60.2% on a year-over-year basis. equities research analysts expect that Novocure will post -0.69 EPS for the current fiscal year.
In other Novocure news, CFO Wilhelmus Cm Groenhuysen sold 1,241 shares of the firm’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $35.01, for a total value of $43,447.41. Following the transaction, the chief financial officer now directly owns 115,644 shares of the company’s stock, valued at approximately $4,048,696.44. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Asaf Danziger sold 11,920 shares of the firm’s stock in a transaction dated Thursday, June 14th. The shares were sold at an average price of $32.00, for a total transaction of $381,440.00. Following the completion of the transaction, the chief executive officer now directly owns 171,100 shares in the company, valued at $5,475,200. The disclosure for this sale can be found here. Insiders sold a total of 398,789 shares of company stock valued at $13,918,687 in the last quarter. Corporate insiders own 15.30% of the company’s stock.
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
See Also: Average Daily Trade Volume Explained
Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.